Shorter Pelvic Radiotherapy After Surgery for Higher-Risk Endometrial Cancer
Tests a 5-session radiotherapy course after surgery in women with endometrial cancer.
Plain-language title generated from the registry record
Registry title: Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)
Key facts
- Where
- Zaragoza, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who had surgery (hysterectomy) for high-intermediate-risk or high-risk endometrial cancer and need radiotherapy to the pelvis afterwards. It tests a short course of 5 radiation sessions.
- Age
- Over 18 years (up to 110 years)
- Sex
- Women only
- Disease stage
- Endometrial cancer confirmed under the microscope after hysterectomy: adenocarcinoma, serous or clear cell carcinoma, carcinosarcoma or dedifferentiated carcinoma. Intermediate-high risk or high risk, based on the 2025 ESGO/ESTRO/ESMO guidelines.
- Earlier treatment
- Must have had a hysterectomy. Must not have had radiotherapy to the pelvis or abdomen before.
Main reasons for not taking part
- Earlier radiotherapy to the pelvis or abdomen
- Inflammatory bowel disease or another reason that rules out pelvic radiotherapy
- Earlier complicated surgery in the abdomen or pelvis
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 110 years old?
Source: NCT07779109, who can take part
Where in Spain
- Unidad Clínica Multihospitalaria de Oncología Radioterápica de Aragón (UCMORA)Zaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Sanitaria Aragón
- Trial code
- NCT07779109
- Record updated
- 25 August 2026
- Original description
The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT/VMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.Read full original descriptionShow less
Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for High-Intermediate and High-Risk Endometrial Cancer: A Prospective Multicenter Phase II Safety Cohort Study
The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT/VMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.
Inclusion: Aged > 18 years; Histologically confirmed diagnosis of endometrial cancer post hysterectomy: endometrial adenocarcinoma, serous or clear cell carcinoma, or carcinosarcoma or dedifferentiated carcinoma; Patients candidates for adjuvant pelvic (Cht)EBRT treatment (+/- vaginal cuff brachytherapy), categorized by Intermediate-high risk and high risk primary endometrial cancer based on recent ESGO/ESTRO/ESMO Guidelines (2025); Patient is willing and able to give informed consent to participate in this clinical trial; Patient must be willing and able to complete the QLQ-C30 questionnaire with EN-24 companion as described in the study protocol; Possibility of fiducial marker placement on vaginal vault; Dosimetric feasibility based on OAR constraint and targets objective.
Exclusion: Prior pelvic or abdominal radiation therapy delivered; Previous abdominal or pelvic complicated surgery; Inflamatory bowel disease of other contraindication to pelvic radiotherapy.